No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Genovate Biotechnology Co., Ltd. is a Taiwanese enterprise dedicated to the research, development, production, and commercialization of various products. These offerings primarily aim to prevent and treat illnesses resulting from viral and bacterial infections. The company's diverse portfolio extends to drugs, active pharmaceutical ingredients (APIs), intermediates, and specialized release agents, which are crucial for addressing a range of health issues including cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune conditions. Complementing its pharmaceutical offerings, Genovate also manufactures controlled-release Western medicine formulations and cosmetic items. Established in 1982, the company's operations are headquartered in Hsinchu City, Taiwan.
www.genovate-bio.comNo one on the platform currently holds 4130.TWO.
No tracked institution reports a position in 4130.TWO as of their last filing.
No one on the platform has traded 4130.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 0.5% | — | — | — | ||
| Rev. Growth % | -3.6% | 0.8% | ||||
| Profit Margin % | 2.4% | 2.0% | ||||
| Free Cash Flow Margin % | -3.6% | -0.5% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $408M | +0.0% | $1.41 | $1.41–$1.41 | — | 1 |
| 2027 | $415M | +1.7% | $0.78 | $0.78–$0.78 | — | 1 |
| 2028 | $510M | +22.9% | $0.44 | $0.44–$0.44 | — | 1 |
| 2029 | $501M | -1.8% | $0.33 | $0.33–$0.33 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-18 | $0.10 | $-0.09 | -192.3% |
| 2026-01-27 | $0.24 | $-0.03 | -113.3% |
| $24.20 |
| +0.83% |
| $1.1B |
| — |
| 6598.TWApplied BioCode Corporation | $27.40 | +0.92% | $2.8B | — |
| 6815.TWODiamond Biotechnology Co., Ltd | $22.50 | -1.10% | $756M | — |
Source: Financial Modeling Prep · peers by sector/industry